NVCR News and Press, NovoCure Limited From 04/02/19

Novocure (NASDAQ:NVCR) announced today that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended Ma...

INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer Ovarian cancer is the fifth leading cause of cancer death among women Novocure (NASDAQ: NVCR) announced today that it has initiated IN...

A special symposium session, intended to highlight therapeutic advances, will focus on Tumor Treating Fields as a fourth modality in cancer treatment The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference Novocure (NAS...

Novocure (NASDAQ: NVCR ) Chief Science Officer and Head of R&D, Dr. Eilon Kirson will retire effective May 1, to spend more time with his family. More news on: NovoCure Limited, Healthcare stocks news, Read more ...

Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019. Dr. Kirson will step away from the healthcare industry and frequent international travel to spend more time with hi...

Novocure (NASDAQ:NVCR) announced today that Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in Oppenheimer’s 29 th Annual Healthcare Conference on March 20, 2019, in New York City. Mr. Groenhuysen’s presentation will begin at 10:55 a.m. EDT. Mr...

NovoCure (NVCR) Q4 2018 Earnings Conference Call February 28, 2019 8:00 AM ET Company Participants Ashley Cordova – Senior Vice President-Finance and Investor Relations Bill Doyle – Executive Chairman Wilco Groenhuysen – Chief Financial Officer Eilon Kirson...

The following slide deck was published by NovoCure in conjunction with their 2018 Q4 earnings Read more ...

NovoCure (NASDAQ: NVCR ): Q4 GAAP EPS of -$0.17 misses by $0.04 . More news on: NovoCure, Earnings news and commentary, Healthcare stocks news, Read more ...

Quarterly net revenues of $69.7 million, representing 30 percent growth versus the fourth quarter 2017 and 8 percent growth versus the third quarter 2018 Full year 2018 net revenues of $248.1 million, representing annual growth of 40 percent compared to 2017 Three additional phase...